All In Biotech

Drug Trial Radar · NCT02558400

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

A Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Subjects With Elevated Intraocular Pressure

Last checked: Nov 19, 2026Latest source record: Jun 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 718 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

718

Actual

Start

Sep 18, 2015

Primary completion

May 17, 2017

Study completion Jun 30, 2017

Sponsor

Lead sponsor
Aerie PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to Netarsudil (AR-13324) Ophthalmic Solution and Latanoprost Ophthalmic Solution. Following completion of the Month 12 study visit procedures, subjects will be offered the opportunity to participate in a 2-month observational (i.e., non-interventional) trial extension.

Conditions

  • Open-angle Glaucoma
  • Ocular Hypertension

Interventions

  • PG324 Ophthalmic Solution 0.02%/0.005%Drug

    1 drop once daily (QD), in the evening (PM) in both eyes (OU)

  • Netarsudil (AR-13324) Ophthalmic Solution 0.02%Drug

    1 drop once daily (QD), in the evening (PM) in both eyes (OU)

  • Latanoprost Ophthalmic Solution 0.005%Drug

    1 drop once daily (QD), in the evening (PM) in both eyes (OU)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular Pressure (IOP)Time frame: Primary efficacy endpoint measured for 3 months (data collected at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aerie Pharmaceuticals

    Bedminster, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.